UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants

Journal of clinical pharmacology, 2009-06, Vol.49 (6), p.643-649

2009

Volltextzugriff (PDF)

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility

Allergy, asthma, and clinical immunology, 2020-04, Vol.16 (1), p.1-26, Article 26

2020

Volltextzugriff (PDF)

The Efficacy and Safety of Beclomethasone Dipropionate Delivered via a Breath-Actuated Inhaler in Adult and Adolescent Patients With Persistent Asthma

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB96-AB96

2017

Volltextzugriff (PDF)

Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974)

British journal of clinical pharmacology, 2010-01, Vol.69 (1), p.15-22

2010

Volltextzugriff (PDF)

Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery

NEJM evidence, 2022-03, Vol.1 (3)

2022

Volltextzugriff (PDF)

Wildlife trade products available to U.S. military personnel serving abroad

Biodiversity and conservation, 2012-04, Vol.21 (4), p.967-980

2012

Volltextzugriff (PDF)

Bioequivalence of Alendronate and Vitamin D3 in a Combination Tablet Versus Corresponding-Dose Individual Tablets in Healthy Taiwanese Volunteers, Determined Using a Novel Plasma Alendronate Assay

Current therapeutic research, 2015-12, Vol.77 (C), p.116-121

2015

Volltextzugriff (PDF)

Potential for Interactions between Caspofungin and Nelfinavir or Rifampin

Antimicrobial Agents and Chemotherapy, 2004-11, Vol.48 (11), p.4306-4314

2004

Volltextzugriff (PDF)

Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.291-300

2006

Volltextzugriff (PDF)

High Peripheral Blood Eosinophil (EOS) Levels Are Associated With Low FEV1 Reversibility (REV) In Patients With Severe Eosinophilic Asthma

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB5-AB5

2019

Volltextzugriff (PDF)

High Peripheral Blood Eosinophil (EOS) Levels Are Associated With Low FEV 1 Reversibility (REV) In Patients With Severe Eosinophilic Asthma

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB5

2019

Volltextzugriff (PDF)

Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB96-AB96

2019

Volltextzugriff (PDF)

Effect of Peanut Ball and Position Changes in Women Laboring With an Epidural

Nursing for women's health, 2019-06, Vol.23 (3), p.245-252

2019

Volltextzugriff (PDF)

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

The New England journal of medicine, 2019-02, Vol.380 (8), p.752-762

2019

Volltextzugriff (PDF)

Intravenous Calcium-/Zinc-Diethylene Triamine Penta-Acetic Acid in Patients With Presumed Gadolinium Deposition Disease: A Preliminary Report on 25 Patients

Investigative radiology, 2018-06, Vol.53 (6), p.373-379

2018

Volltextzugriff (PDF)

Evaluation of Eosinophilic Asthma Patients Without Blood Eosinophil (EOS) Response to Intravenous (IV) Reslizumab in a Post-Hoc Analysis of 52-Week Placebo-Controlled Phase 3 Studies

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB97-AB97

2019

Volltextzugriff (PDF)

A High Proportion Of Exacerbation-Prone Patients With Uncontrolled Eosinophilic Asthma Receiving IV Reslizumab Experienced Zero Asthma Exacerbations Through 52 Weeks (wks) Of Treatment

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB98-AB98

2019

Volltextzugriff (PDF)

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

The lancet respiratory medicine, 2020-05, Vol.8 (5), p.461-474

2020

Volltextzugriff (PDF)

Relationship between handheld and clinic-based spirometry measurements in asthma patients receiving beclomethasone

Respiratory medicine, 2019-05, Vol.151, p.35-42

2019

Volltextzugriff (PDF)

Efficacy of Intravenous Reslizumab in Oral Corticosteroid–Dependent Asthma

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-02, Vol.8 (2), p.555-564

2020

Volltextzugriff (PDF)

Starting the Garden with Transplants: HS507/VH027, rev. 1/2022

EDIS, 2022-01, Vol.2022 (1)

2022

Volltextzugriff (PDF)

Starting the Garden with Transplants

EDIS, 2022-01, Vol.2022 (1)

2022

Volltextzugriff (PDF)

Efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma

Allergy and asthma proceedings, 2017-09, Vol.38 (5), p.354-364

2017

Volltextzugriff (PDF)

Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant

Clinical pharmacokinetics, 2005-01, Vol.44 (6), p.637-647

2005

Volltextzugriff (PDF)

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV 1 reversibility

Allergy, asthma, and clinical immunology, 2020, Vol.16, p.26

2020

Volltextzugriff (PDF)

1 – 25 von 268

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(245)
Mit Volltextzugriff
(216)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(268)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility

The Efficacy and Safety of Beclomethasone Dipropionate Delivered via a Breath-Actuated Inhaler in Adult and Adolescent Patients With Persistent Asthma

Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974)

Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery

Wildlife trade products available to U.S. military personnel serving abroad

Bioequivalence of Alendronate and Vitamin D3 in a Combination Tablet Versus Corresponding-Dose Individual Tablets in Healthy Taiwanese Volunteers, Determined Using a Novel Plasma Alendronate Assay

Potential for Interactions between Caspofungin and Nelfinavir or Rifampin

Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

High Peripheral Blood Eosinophil (EOS) Levels Are Associated With Low FEV1 Reversibility (REV) In Patients With Severe Eosinophilic Asthma

High Peripheral Blood Eosinophil (EOS) Levels Are Associated With Low FEV 1 Reversibility (REV) In Patients With Severe Eosinophilic Asthma

Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab

Effect of Peanut Ball and Position Changes in Women Laboring With an Epidural

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Intravenous Calcium-/Zinc-Diethylene Triamine Penta-Acetic Acid in Patients With Presumed Gadolinium Deposition Disease: A Preliminary Report on 25 Patients

Evaluation of Eosinophilic Asthma Patients Without Blood Eosinophil (EOS) Response to Intravenous (IV) Reslizumab in a Post-Hoc Analysis of 52-Week Placebo-Controlled Phase 3 Studies

A High Proportion Of Exacerbation-Prone Patients With Uncontrolled Eosinophilic Asthma Receiving IV Reslizumab Experienced Zero Asthma Exacerbations Through 52 Weeks (wks) Of Treatment

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

Relationship between handheld and clinic-based spirometry measurements in asthma patients receiving beclomethasone

Efficacy of Intravenous Reslizumab in Oral Corticosteroid–Dependent Asthma

Starting the Garden with Transplants: HS507/VH027, rev. 1/2022

Starting the Garden with Transplants

Efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma

Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV 1 reversibility

Suchergebnisse filtern